ClinicalTrials.gg
CompletedNCT03418922Updated Jun 20, 2024Results posted

A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma

A Phase 1 interventional study of Lenvatinib and Nivolumab in Carcinoma, Hepatocellular, sponsored by Eisai Co., Ltd.. Completed at 6 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-06-20.

Sponsored by Eisai Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 121 studies testing lenvatinib in Carcinoma, Hepatocellular — 57 open to participants now, 65 under way, 7 of them phase 3. lenvatinib · Carcinoma, Hepatocellular.

Enrollment
89th of 121
30 · median 48
Started
2018
with 5 others
Phase 1
9 of 121
4 open now
Registered
5th of 121
by date
Lead sponsor
4 of 121
Eisai Co., Ltd.

Among the 121 studies testing lenvatinib in Carcinoma, Hepatocellular, this one is the 89th largest by enrollment, is one of 6 that started in 2018, is one of 9 in phase 1, and was the 5th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

57 of the 121 studies testing lenvatinib in Carcinoma, Hepatocellular are open now, in 6 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies testing lenvatinib in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the tolerability and safety of a combination of lenvatinib plus nivolumab in participants with hepatocellular carcinoma (HCC).

03

Conditions studied

  • Carcinoma, Hepatocellular
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have confirmed diagnosis of hepatocellular carcinoma (HCC) with any of the following criteria:

    • or cytologically confirmed diagnosis of HCC, excluding fibrolamellar, sarcomatoid or mixed cholangio-HCC tumors
    • Clinically confirmed diagnosis of HCC according to American Association for the Study of Liver Diseases criteria, including cirrhosis of any etiology and/or chronic or C infection
  • Part 1: HCC for which no other appropriate therapy is available; Part 2: No prior systemic therapy for advanced/unresectable HCC
  • Participants categorized to stage B (not applicable for transarterial chemoembolization), or stage C based on Barcelona Clinic Liver Cancer staging system
  • score A
  • Participants must have an Performance Status of 0 to 1
  • Age greater than or equal to (>=) 20 years at the time of

Exclusion criteria

Exclusion Criteria:

  • Active co-infection with and
  • Participants with any active, known, or suspected disease
  • Participants being treated with drugs that strongly inhibit or induce and that may be possibly used during this study
  • Females who are breastfeeding or pregnant
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Part 1: Lenvatinib Plus Nivolumab

    Participants will receive specified doses of lenvatinib (oral) and nivolumab (intravenous) on specified days.

    Drug: Lenvatinib · Drug: Nivolumab

  • Experimental
    Part 2: Lenvatinib Plus Nivolumab

    If tolerable in Part 1, participants will receive specified doses of lenvatinib and nivolumab on specified days until criteria for discontinuation are met.

    Drug: Lenvatinib · Drug: Nivolumab

Interventions

  • Specified doses will be administered orally on specified days.

  • Specified doses will be administered intravenously on specified days.

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Dose-Limiting Toxicities (DLTs)

    DLT was graded according to Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v4.03). DLT was defined as any of the following hematological or non-hematological toxicities considered to be at least possibly related to lenvatinib and/or nivolumab occurring during Cycle 1: 1) Febrile neutropenia or Grade 4 neutropenia for \>7 days; 2) Grade 4 thrombocytopenia and Grade 3 thrombocytopenia with bleeding; 3) Grade 4 anemia; 4) Clinical deterioration manifested by drug-related hepatic decompensation; 5) \>=Grade 3 non-hematological laboratory abnormalities with clinical symptoms that persisted; 6) Other Grade 3 toxicity lasting \>3 days or Grade 4 non-hematological toxicity of any duration; 7) Grade 2 uveitis, eye pain, or blurred vision that did not respond to topical therapy; 8) Failure to administer 8 or more dose of the planned administration number of study drug in Cycle 1 as a result of treatment-related toxicity.

    Time frame: Cycle 1 (Cycle length = 28 days)

  2. Part 1 and Part 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    A TEAE was defined as an adverse event (AE) that emerged during treatment and until the 30 days after the last dose or until the participants initiated new anticancer therapy, whichever was earlier, was absent at pretreatment (Baseline) or reemerged during treatment, was present at pretreatment (Baseline) but stopped before treatment, or worsened in severity during treatment relative to the pretreatment state, when the AE was continuous. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening (that is, participant was at immediate risk of death from AE as it occurred; this did not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug).

    Time frame: From the first dose of study drug until 30 days after the last dose (up to 53 months)

  3. Mean Change From Baseline in Vital Sign: Weight

    Mean change from baseline in weight were evaluated.

    Time frame: Baseline, up to Month 53

  4. Mean Change From Baseline in Vital Sign: Body Mass Index

    Mean change from baseline in body mass index were evaluated.

    Time frame: Baseline, up to Month 53

  5. Mean Change From Baseline in Vital Sign: SpO2 (Oxygen Saturation)

    Mean change from baseline in SpO2 were evaluated.

    Time frame: Baseline, up to Month 53

  6. Number of Participants With Treatment-Emergent Markedly Abnormal Laboratory Values (TEMAVs)

    Treatment-emergent markedly abnormal laboratory value was defined as a postbaseline laboratory value with grade 3 or higher, and with a grade increase from baseline, (that is \[i.e.\] increasing grade 0 to 3 or higher, grade 1 to 3 or higher, grade 2 to 3 or higher, grade 3 to 4 or 5, grade 4 to 5). Test abnormalities were graded by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 as Grade 1 =mild; Grade 2 =moderate; Grade 3/Grade 4 =severe/life-threatening, Grade 5 =death.

    Time frame: From the first dose of study drug until 30 days after the last dose (up to 53 months)

  7. Number of Participants With Highest Post-Baseline Values for Eastern Cooperative Oncology Group Performance Status (ECOG-PS) Scale

    Performance status assessments were based on 5-grade ECOG scale (from 0 to 4), where 0=fully active, able to carry on all pre-disease performance without restriction; 1=restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (e.g., light house work, office work); 2=ambulatory and capable of all self-care but unable to carry out any work activities, up and about more than 50% of waking hours; 3=capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4=completely disabled, cannot carry on any self-care, totally confined to bed or chair; 5=dead.

    Time frame: Baseline, up to Month 53

  8. Change From Baseline in Left Ventricular Ejection Fraction (LVEF)

    Change from baseline in left ventricular ejection fraction (LVEF) were evaluated by multigated acquisition scan (MUGA) or echocardiogram.

    Time frame: Baseline, up to Month 53

Secondary outcomes

  1. Part 1 and Part 2: Objective Response Rate (ORR) Based on Modified Response Evaluation Criteria in Solid Tumors (mRECIST) Assessed by Investigator Review

    ORR was defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) based on mRECIST assessed by investigator review. CR defined as disappearance of all target lesions and non-target lesions (a short diameter is less than 10 millimeters \[mm\] if it exists in a lymph node). PR defined as at least 30% decrease in the sum of diameter of all target lesions without unequivocal progression of all non-target lesions, as compared with Baseline.

    Time frame: From the first dose of study drug to the first date of documentation of PD or death, whichever occurred first (up to 52 months)

  2. Part 1, Cmax: Maximum Observed Plasma Concentration for Lenvatinib

    Cmax was defined as the maximum plasma concentration for lenvatinib. Cmax was derived by non-compartmental analysis using lenvatinib plasma concentrations.

    Time frame: Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=28 days)

  3. Part 1, Tmax: Time to Reach the Cmax for Lenvatinib

    Tmax was defined as the time to reach maximum observed plasma concentration (Cmax) for lenvatinib. Tmax was derived by non-compartmental analysis using lenvatinib plasma concentrations.

    Time frame: Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=28 days)

  4. Part 1, AUC(0-t): Area Under the Plasma Concentration-time Curve From Zero Time to the Last Measurable Point for Lenvatinib

    AUC(0-t) was defined as the area under the plasma concentration-time curve from 0 time to last measurable point for lenvatinib. AUC(0-t) was derived by non-compartmental analysis using lenvatinib plasma concentrations.

    Time frame: Cycle 1 Day 1 and Day 15: 0-24 hours post-dose (Cycle length=28 days)

  5. Part 1, AUC(0-Inf): Area Under the Plasma Concentration-time Curve From Zero to Infinity for Lenvatinib

    AUC(0-Inf) was defined as the area under the plasma concentration-time curve from 0 to infinity for lenvatinib. AUC(0-Inf) was derived by non-compartmental analysis using lenvatinib plasma concentrations.

    Time frame: Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=28 days)

  6. Part 1, t1/2: Terminal Elimination Phase Half-Life for Lenvatinib

    t1/2 was defined as the terminal elimination phase half-life for lenvatinib. t1/2 was derived by non-compartmental analysis using lenvatinib plasma concentrations.

    Time frame: Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=28 days)

  7. Part 1, CL/F: Apparent Total Clearance for Lenvatinib

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as (Dose/AUC(0-inf))/F. Where AUC(0-inf) is the area under the plasma concentration-time curve from zero to infinity and F is the bioavailability of the drug.

    Time frame: Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=28 days)

  8. Part 1, Vz/F: Apparent Terminal Volume of Distribution for Lenvatinib

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F was calculated as (CL/F)/Lambda Z. Where, CL/F is the apparent total clearance and lambda Z is the apparent terminal elimination rate constant.

    Time frame: Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=28 days)

  9. Part 1, Css,Max: Maximum Observed Plasma Concentration at Steady State for Lenvatinib

    Css,max was defined as the maximum plasma concentration at steady state for lenvatinib. Css,max was derived by non-compartmental analysis using lenvatinib plasma concentrations.

    Time frame: Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=28 days)

  10. Part 1, Css,Min: Minimum Observed Plasma Concentration at Steady State for Lenvatinib

    Css,min is the minimum plasma concentration at steady state for lenvatinib. Css,min was derived by non-compartmental analysis using lenvatinib plasma concentrations.

    Time frame: Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=28 days)

  11. Part 1, Tss,Max: Time to Maximum Observed Concentration at Steady State For Lenvatinib

    Tss,Max was defined as the time to reach maximum observed plasma concentration of lenvatinib at steady state. Tss,Max was derived by non-compartmental analysis using lenvatinib plasma concentrations.

    Time frame: Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=28 days)

  12. Part 1, Rac (Cmax): Accumulation Ratio of Cmax for Lenvatinib

    Rac(Cmax) was calculated as Css,max at Cycle 1 Day 15/Cmax at Cycle 1 Day 1.

    Time frame: Cycle 1 Day 1 and Day 15: 0-24 hours post-dose (Cycle length=28 days)

  13. Part 1, Rac (AUC0-t): Accumulation Ratio of AUC(0-t) for Lenvatinib

    Rac(AUC) was calculated as AUC(0-t) at Cycle 1 Day 15/AUC(0-t) at Cycle 1 Day 1.

    Time frame: Cycle 1 Day 1 and Day 15: 0-24 hours post-dose (Cycle length=28 days)

  14. Part 1, MRT: Mean Residence Time for Lenvatinib

    MRT was derived by non-compartmental analysis using lenvatinib plasma concentrations.

    Time frame: Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=28 days)

07

Results

Posted Jun 20, 2024

Participant flow

The study was conducted in two parts (Part 1 and Part 2) between 16 January 2018 and 28 December 2022 at 1 site for Part 1 and 6 sites for Part 2 in Japan.

Participant flow — Overall Study
MilestonePart 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mgPart 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg
Started624
Completed418
Not completed26
Withdrew: Withdrawal by subject02
Withdrew: Adverse event22
Withdrew: Death01
Withdrew: Physician decision01

Outcome measures

PrimaryPart 1: Number of Participants With Dose-Limiting Toxicities (DLTs)

DLT was graded according to Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v4.03). DLT was defined as any of the following hematological or non-hematological toxicities considered to be at least possibly related to lenvatinib and/or nivolumab occurring during Cycle 1: 1) Febrile neutropenia or Grade 4 neutropenia for \>7 days; 2) Grade 4 thrombocytopenia and Grade 3 thrombocytopenia with bleeding; 3) Grade 4 anemia; 4) Clinical deterioration manifested by drug-related hepatic decompensation; 5) \>=Grade 3 non-hematological laboratory abnormalities with clinical symptoms that persisted; 6) Other Grade 3 toxicity lasting \>3 days or Grade 4 non-hematological toxicity of any duration; 7) Grade 2 uveitis, eye pain, or blurred vision that did not respond to topical therapy; 8) Failure to administer 8 or more dose of the planned administration number of study drug in Cycle 1 as a result of treatment-related toxicity.

Time frame:
Cycle 1 (Cycle length = 28 days)
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Dose-Limiting Toxicities (DLTs)
ParticipantsPart 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg
Part 1: Number of Participants With Dose-Limiting Toxicities (DLTs)0
PrimaryPart 1 and Part 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

A TEAE was defined as an adverse event (AE) that emerged during treatment and until the 30 days after the last dose or until the participants initiated new anticancer therapy, whichever was earlier, was absent at pretreatment (Baseline) or reemerged during treatment, was present at pretreatment (Baseline) but stopped before treatment, or worsened in severity during treatment relative to the pretreatment state, when the AE was continuous. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening (that is, participant was at immediate risk of death from AE as it occurred; this did not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug).

Time frame:
From the first dose of study drug until 30 days after the last dose (up to 53 months)
Reported as:
Count of participants · Participants
Part 1 and Part 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsPart 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mgPart 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg
TEAEs624
SAEs312
PrimaryMean Change From Baseline in Vital Sign: Weight

Mean change from baseline in weight were evaluated.

Time frame:
Baseline, up to Month 53
Reported as:
Mean · kilogram
Mean Change From Baseline in Vital Sign: Weight
kilogramPart 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mgPart 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg
Mean Change From Baseline in Vital Sign: Weight2.82 ± 3.931-3.10 ± 4.953
PrimaryMean Change From Baseline in Vital Sign: Body Mass Index

Mean change from baseline in body mass index were evaluated.

Time frame:
Baseline, up to Month 53
Reported as:
Mean · kilogram per square meter
Mean Change From Baseline in Vital Sign: Body Mass Index
kilogram per square meterPart 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mgPart 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg
Mean Change From Baseline in Vital Sign: Body Mass Index1.10 ± 1.434-1.12 ± 1.811
PrimaryMean Change From Baseline in Vital Sign: SpO2 (Oxygen Saturation)

Mean change from baseline in SpO2 were evaluated.

Time frame:
Baseline, up to Month 53
Reported as:
Mean · percentage of blood oxygen saturation
Mean Change From Baseline in Vital Sign: SpO2 (Oxygen Saturation)
percentage of blood oxygen saturationPart 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mgPart 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg
Mean Change From Baseline in Vital Sign: SpO2 (Oxygen Saturation)0.2 ± 0.75-0.6 ± 1.41
PrimaryNumber of Participants With Treatment-Emergent Markedly Abnormal Laboratory Values (TEMAVs)

Treatment-emergent markedly abnormal laboratory value was defined as a postbaseline laboratory value with grade 3 or higher, and with a grade increase from baseline, (that is \[i.e.\] increasing grade 0 to 3 or higher, grade 1 to 3 or higher, grade 2 to 3 or higher, grade 3 to 4 or 5, grade 4 to 5). Test abnormalities were graded by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 as Grade 1 =mild; Grade 2 =moderate; Grade 3/Grade 4 =severe/life-threatening, Grade 5 =death.

Time frame:
From the first dose of study drug until 30 days after the last dose (up to 53 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Markedly Abnormal Laboratory Values (TEMAVs)
ParticipantsPart 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mgPart 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg
Hemoglobin: Markedly Abnormal Low02
Hemoglobin: Markedly Abnormal High00
Platelets: Markedly Abnormal Low21
Leukocytes: Markedly Abnormal Low00
Leukocytes: Markedly Abnormal High00
Lymphocytes: Markedly Abnormal Low24
Lymphocytes: Markedly Abnormal High00
Neutrophils: Markedly Abnormal Low03
Prothrombin international normalized ratio: Markedly Abnormal High00
Alkaline phosphatase: Markedly Abnormal High01
Aspartate aminotransferase: Markedly Abnormal High06
Alanine aminotransferase: Markedly Abnormal High11
Gamma-glutamyl transferase: Markedly Abnormal High16
Bilirubin: Markedly Abnormal High03
Creatinine: Markedly Abnormal High10
Glucose: Markedly Abnormal Low00
Glucose: Markedly Abnormal High04
Albumin: Markedly Abnormal Low12
Cholesterol: Markedly Abnormal High00
Triglycerides: Markedly Abnormal High01
Phosphate: Markedly Abnormal Low03
Sodium: Markedly Abnormal Low03
Sodium: Markedly Abnormal High00
Potassium: Markedly Abnormal Low03
Potassium: Markedly Abnormal High00
Calcium corrected: Markedly Abnormal Low00
Calcium corrected: Markedly Abnormal High00
Magnesium: Markedly Abnormal Low01
Magnesium: Markedly Abnormal High00
Amylase: Markedly Abnormal High11
Lipase: Markedly Abnormal High35
PrimaryNumber of Participants With Highest Post-Baseline Values for Eastern Cooperative Oncology Group Performance Status (ECOG-PS) Scale

Performance status assessments were based on 5-grade ECOG scale (from 0 to 4), where 0=fully active, able to carry on all pre-disease performance without restriction; 1=restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (e.g., light house work, office work); 2=ambulatory and capable of all self-care but unable to carry out any work activities, up and about more than 50% of waking hours; 3=capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4=completely disabled, cannot carry on any self-care, totally confined to bed or chair; 5=dead.

Time frame:
Baseline, up to Month 53
Reported as:
Count of participants · Participants
Number of Participants With Highest Post-Baseline Values for Eastern Cooperative Oncology Group Performance Status (ECOG-PS) Scale
ParticipantsPart 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mgPart 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg
Grade 0015
Grade 156
Grade 201
Grade 312
Grade 400
PrimaryChange From Baseline in Left Ventricular Ejection Fraction (LVEF)

Change from baseline in left ventricular ejection fraction (LVEF) were evaluated by multigated acquisition scan (MUGA) or echocardiogram.

Time frame:
Baseline, up to Month 53
Reported as:
Mean · %LVEF
Change From Baseline in Left Ventricular Ejection Fraction (LVEF)
%LVEFPart 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mgPart 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg
Change From Baseline in Left Ventricular Ejection Fraction (LVEF)0.0 ± 2.000.4 ± 4.65
SecondaryPart 1 and Part 2: Objective Response Rate (ORR) Based on Modified Response Evaluation Criteria in Solid Tumors (mRECIST) Assessed by Investigator Review

ORR was defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) based on mRECIST assessed by investigator review. CR defined as disappearance of all target lesions and non-target lesions (a short diameter is less than 10 millimeters \[mm\] if it exists in a lymph node). PR defined as at least 30% decrease in the sum of diameter of all target lesions without unequivocal progression of all non-target lesions, as compared with Baseline.

Time frame:
From the first dose of study drug to the first date of documentation of PD or death, whichever occurred first (up to 52 months)
Reported as:
Number · percentage of participants
Part 1 and Part 2: Objective Response Rate (ORR) Based on Modified Response Evaluation Criteria in Solid Tumors (mRECIST) Assessed by Investigator Review
percentage of participantsPart 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mgPart 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg
Part 1 and Part 2: Objective Response Rate (ORR) Based on Modified Response Evaluation Criteria in Solid Tumors (mRECIST) Assessed by Investigator Review66.7 (22.3 to 95.7)79.2 (57.8 to 92.9)
SecondaryPart 1, Cmax: Maximum Observed Plasma Concentration for Lenvatinib

Cmax was defined as the maximum plasma concentration for lenvatinib. Cmax was derived by non-compartmental analysis using lenvatinib plasma concentrations.

Time frame:
Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=28 days)
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Part 1, Cmax: Maximum Observed Plasma Concentration for Lenvatinib
nanogram per milliliter (ng/mL)Lenvatinib 8 mg + Nivolumab 240 mgLenvatinib 12 mg + Nivolumab 240 mg
Part 1, Cmax: Maximum Observed Plasma Concentration for Lenvatinib93.3 ± 16.8122 ± 46.3
SecondaryPart 1, Tmax: Time to Reach the Cmax for Lenvatinib

Tmax was defined as the time to reach maximum observed plasma concentration (Cmax) for lenvatinib. Tmax was derived by non-compartmental analysis using lenvatinib plasma concentrations.

Time frame:
Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=28 days)
Reported as:
Median · hours
Part 1, Tmax: Time to Reach the Cmax for Lenvatinib
hoursLenvatinib 8 mg + Nivolumab 240 mgLenvatinib 12 mg + Nivolumab 240 mg
Part 1, Tmax: Time to Reach the Cmax for Lenvatinib1.45 (0.87 to 2.02)3.97 (1.80 to 7.52)
SecondaryPart 1, AUC(0-t): Area Under the Plasma Concentration-time Curve From Zero Time to the Last Measurable Point for Lenvatinib

AUC(0-t) was defined as the area under the plasma concentration-time curve from 0 time to last measurable point for lenvatinib. AUC(0-t) was derived by non-compartmental analysis using lenvatinib plasma concentrations.

Time frame:
Cycle 1 Day 1 and Day 15: 0-24 hours post-dose (Cycle length=28 days)
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*h/mL)
Part 1, AUC(0-t): Area Under the Plasma Concentration-time Curve From Zero Time to the Last Measurable Point for Lenvatinib
nanogram*hour per milliliter (ng*h/mL)Lenvatinib 8 mg + Nivolumab 240 mgLenvatinib 12 mg + Nivolumab 240 mg
Cycle 1 Day 1882 ± 0.08011380 ± 36.0
Cycle 1 Day 151410 ± 16.71920 ± 17.2
SecondaryPart 1, AUC(0-Inf): Area Under the Plasma Concentration-time Curve From Zero to Infinity for Lenvatinib

AUC(0-Inf) was defined as the area under the plasma concentration-time curve from 0 to infinity for lenvatinib. AUC(0-Inf) was derived by non-compartmental analysis using lenvatinib plasma concentrations.

Time frame:
Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=28 days)
Reported as:
Geometric mean · ng*h/mL
Part 1, AUC(0-Inf): Area Under the Plasma Concentration-time Curve From Zero to Infinity for Lenvatinib
ng*h/mLLenvatinib 8 mg + Nivolumab 240 mgLenvatinib 12 mg + Nivolumab 240 mg
Part 1, AUC(0-Inf): Area Under the Plasma Concentration-time Curve From Zero to Infinity for Lenvatinib987 ± 6.101630 ± NA
SecondaryPart 1, t1/2: Terminal Elimination Phase Half-Life for Lenvatinib

t1/2 was defined as the terminal elimination phase half-life for lenvatinib. t1/2 was derived by non-compartmental analysis using lenvatinib plasma concentrations.

Time frame:
Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=28 days)
Reported as:
Geometric mean · hours
Part 1, t1/2: Terminal Elimination Phase Half-Life for Lenvatinib
hoursLenvatinib 8 mg + Nivolumab 240 mgLenvatinib 12 mg + Nivolumab 240 mg
Part 1, t1/2: Terminal Elimination Phase Half-Life for Lenvatinib6.77 ± 27.18.95 ± NA
SecondaryPart 1, CL/F: Apparent Total Clearance for Lenvatinib

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as (Dose/AUC(0-inf))/F. Where AUC(0-inf) is the area under the plasma concentration-time curve from zero to infinity and F is the bioavailability of the drug.

Time frame:
Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=28 days)
Reported as:
Geometric mean · liter per hour (L/h)
Part 1, CL/F: Apparent Total Clearance for Lenvatinib
liter per hour (L/h)Lenvatinib 8 mg + Nivolumab 240 mgLenvatinib 12 mg + Nivolumab 240 mg
Part 1, CL/F: Apparent Total Clearance for Lenvatinib8.09 ± 6.307.37 ± NA
SecondaryPart 1, Vz/F: Apparent Terminal Volume of Distribution for Lenvatinib

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F was calculated as (CL/F)/Lambda Z. Where, CL/F is the apparent total clearance and lambda Z is the apparent terminal elimination rate constant.

Time frame:
Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=28 days)
Reported as:
Geometric mean · liter
Part 1, Vz/F: Apparent Terminal Volume of Distribution for Lenvatinib
literLenvatinib 8 mg + Nivolumab 240 mgLenvatinib 12 mg + Nivolumab 240 mg
Part 1, Vz/F: Apparent Terminal Volume of Distribution for Lenvatinib79.0 ± 20.495.1 ± NA
SecondaryPart 1, Css,Max: Maximum Observed Plasma Concentration at Steady State for Lenvatinib

Css,max was defined as the maximum plasma concentration at steady state for lenvatinib. Css,max was derived by non-compartmental analysis using lenvatinib plasma concentrations.

Time frame:
Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=28 days)
Reported as:
Geometric mean · ng/mL
Part 1, Css,Max: Maximum Observed Plasma Concentration at Steady State for Lenvatinib
ng/mLLenvatinib 8 mg + Nivolumab 240 mgLenvatinib 12 mg + Nivolumab 240 mg
Part 1, Css,Max: Maximum Observed Plasma Concentration at Steady State for Lenvatinib139 ± 29.5164 ± 9.93
SecondaryPart 1, Css,Min: Minimum Observed Plasma Concentration at Steady State for Lenvatinib

Css,min is the minimum plasma concentration at steady state for lenvatinib. Css,min was derived by non-compartmental analysis using lenvatinib plasma concentrations.

Time frame:
Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=28 days)
Reported as:
Geometric mean · ng/mL
Part 1, Css,Min: Minimum Observed Plasma Concentration at Steady State for Lenvatinib
ng/mLLenvatinib 8 mg + Nivolumab 240 mgLenvatinib 12 mg + Nivolumab 240 mg
Part 1, Css,Min: Minimum Observed Plasma Concentration at Steady State for Lenvatinib13.5 ± 15.828.2 ± 48.7
SecondaryPart 1, Tss,Max: Time to Maximum Observed Concentration at Steady State For Lenvatinib

Tss,Max was defined as the time to reach maximum observed plasma concentration of lenvatinib at steady state. Tss,Max was derived by non-compartmental analysis using lenvatinib plasma concentrations.

Time frame:
Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=28 days)
Reported as:
Median · hours
Part 1, Tss,Max: Time to Maximum Observed Concentration at Steady State For Lenvatinib
hoursLenvatinib 8 mg + Nivolumab 240 mgLenvatinib 12 mg + Nivolumab 240 mg
Part 1, Tss,Max: Time to Maximum Observed Concentration at Steady State For Lenvatinib3.94 (3.85 to 4.02)3.93 (3.92 to 7.98)
SecondaryPart 1, Rac (Cmax): Accumulation Ratio of Cmax for Lenvatinib

Rac(Cmax) was calculated as Css,max at Cycle 1 Day 15/Cmax at Cycle 1 Day 1.

Time frame:
Cycle 1 Day 1 and Day 15: 0-24 hours post-dose (Cycle length=28 days)
Reported as:
Geometric mean · ratio
Part 1, Rac (Cmax): Accumulation Ratio of Cmax for Lenvatinib
ratioLenvatinib 8 mg + Nivolumab 240 mgLenvatinib 12 mg + Nivolumab 240 mg
Part 1, Rac (Cmax): Accumulation Ratio of Cmax for Lenvatinib1.48 ± 12.41.28 ± 62.4
SecondaryPart 1, Rac (AUC0-t): Accumulation Ratio of AUC(0-t) for Lenvatinib

Rac(AUC) was calculated as AUC(0-t) at Cycle 1 Day 15/AUC(0-t) at Cycle 1 Day 1.

Time frame:
Cycle 1 Day 1 and Day 15: 0-24 hours post-dose (Cycle length=28 days)
Reported as:
Geometric mean · ratio
Part 1, Rac (AUC0-t): Accumulation Ratio of AUC(0-t) for Lenvatinib
ratioLenvatinib 8 mg + Nivolumab 240 mgLenvatinib 12 mg + Nivolumab 240 mgEdit
Part 1, Rac (AUC0-t): Accumulation Ratio of AUC(0-t) for Lenvatinib1.59 ± 17.01.38 ± 47.1
SecondaryPart 1, MRT: Mean Residence Time for Lenvatinib

MRT was derived by non-compartmental analysis using lenvatinib plasma concentrations.

Time frame:
Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=28 days)
Reported as:
Median · hours
Part 1, MRT: Mean Residence Time for Lenvatinib
hoursLenvatinib 8 mg + Nivolumab 240 mgLenvatinib 12 mg + Nivolumab 240 mg
Part 1, MRT: Mean Residence Time for Lenvatinib10.9 (9.35 to 12.4)13.7 (13.7 to 13.7)

Adverse events

Collected over From the first dose of study drug until 30 days after the last dose (up to 53 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg1/6 (16.7%)3/6 (50%)6/6 (100%)
Part 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg18/24 (75%)12/24 (50%)24/24 (100%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventPart 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mgPart 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg
HyperthyroidismEndocrine disorders1/60/24
DiarrhoeaGastrointestinal disorders1/60/24
BronchitisInfections and infestations1/60/24
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders1/60/24
Hepatic encephalopathyNervous system disorders0/62/24
LymphadenitisBlood and lymphatic system disorders0/61/24
Adrenal insufficiencyEndocrine disorders0/61/24
Adrenocorticotropic hormone deficiencyEndocrine disorders0/61/24
OedemaGeneral disorders0/61/24
Oedema peripheralGeneral disorders0/61/24
Most frequent other events
Showing 10 of 131
Most frequent other events
EventPart 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mgPart 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mg
FatigueGeneral disorders5/64/24
DiarrhoeaGastrointestinal disorders4/615/24
NauseaGastrointestinal disorders4/64/24
Decreased appetiteMetabolism and nutrition disorders4/611/24
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders2/616/24
DysphoniaRespiratory, thoracic and mediastinal disorders3/613/24
HypothyroidismEndocrine disorders3/67/24
ProteinuriaRenal and urinary disorders3/611/24
HypertensionVascular disorders1/610/24
MalaiseGeneral disorders0/69/24

Baseline characteristics

Safety analysis set included all participants who received at least 1 dose of lenvatinib or nivolumab.

Age, Continuous
Age, Continuous(Years)Part 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mgPart 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mgTotal
Mean73.5 ± 1.8767.1 ± 10.7468.4 ± 9.94
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mgPart 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mgTotal
Female156
Male51924
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mgPart 2: Lenvatinib 12 mg or 8 mg + Nivolumab 240 mgTotal
Japanese62329
Chinese011
08

Study locations

6 sites
  • Eisai Trial Site 1
    Kashiwa, Chiba, Japan
  • Eisai Trial Site 6
    Iizuka, Fukuoka, Japan
  • Eisai Trial Site 3
    Kawasaki, Kanagawa, Japan
  • Eisai Trial Site 4
    Osakasayama, Osaka, Japan
  • Eisai Trial Site 2
    Chuo-ku, Tokyo, Japan
  • Eisai Trial Site 5
    Chiba, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Dec 2022, 59 months.

Results were first posted in Jun 2024, 1 year 5 months after primary completion.

Of 103 industry-sponsored phase 1 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's 59 months is above that.

Counting every sponsor, half of 248 studies reached it within 49 months; a quarter within 32 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2018
First posted
Feb 1, 2018
StartActual
Jan 16, 2018
Primary completionActual
Dec 28, 2022
CompletionActual
Dec 28, 2022
Results first posted
Jun 20, 2024
Last update
Jun 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03418922
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Feb 1, 2018
Start date
Jan 16, 2018
Primary completion
Dec 28, 2022
Completion
Dec 28, 2022
Results posted
Jun 20, 2024
Last update
Jun 20, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenvatinib · Nivolumab

Start the discussion